Lausanne, Switzerland, February 21, 2008 – Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, announces the signature of a License and Supply Agreement with Medical Futures Inc., a Canadian based Gastroenterology focused speciality pharmaceutical company, for the Canadian distribution rights to SANVAR® IR (SANVAR®), an immediate release formulation. The product, developed by Debiopharm for the treatment of acute esophageal variceal bleeding (EVB), is currently under review for approval by the Canadian Health Authorities. In addition to purchasing the product directly from Debiopharm, Medical Futures Inc. is responsible for upfront and milestone payments.
